We employed a rat model of bone prostate cancer pain to test the hypothesis that XZP can alleviate bone cancer pain by modulating the RANKL/RANK/OPG signaling and the expression of bone metabolic regulators of PTHrP and IGF-1 and inflammatory mediators of IL-8, M-CSF, and TNF-α in the bone of rats. This evidence concerns the gene IGF1 and bone neoplasm.